



In an ongoing effort to provide appropriate, affordable, healthcare options to our members, Willamette Valley Community Health CCO will be making several changes to the current formulary.

All formulary changes, additions and removals are thoroughly investigated, reviewed and approved by the Pharmacy & Therapeutics Committee. This Committee is comprised of several providers representing multiple specialties and clinics from our community. These recommendations were based on utilization, pharmacokinetic information and cost data.

We value your partnership as we continue to work toward our mutual goal of delivering the highest quality healthcare while ensuring affordability and accessibility. If you are interested in participating in the P & T Committee please contact the Clinical Pharmacists at 503-371-7701 for more information.

WVCH Formulary Additions Effective 10/7/2017				
Name	Strength	Dosage Form	Route	Change
Fluticasone/Salmeterol Resplick	55 mcg/14 mcg, 113 mcg/14 mcg, 232 mcg/14 mcg	Inhaler	Oral	On formulary with NSO PA
Suprep	17.5-3.13-1.6 GM/180 ML	Solution	Oral	Add to formulary
Trulicity	0.75 mg/0.5 ml and 1.5 mg/0.5 ml	Solution pen-injector	SubQ injection	Add to formulary with PA
Victoza	18 mg/3 ml	Solution pen-injector	SubQ injection	Add to formulary with PA
Tradjenta	5 mg	Tablet	Oral	Add to formulary with PA
WVCH Formulary Changes Effective 11/7/2017				
Name	Strength	Dosage Form	Route	Change
Asmanex (mometasone furoate)	110 mcg, 220 mcg	Twisthaler	Oral	Adding a QL of 1 inhaler every 30 days

Questions? Please contact WVCH at 503-584-2150 posted 10.06.2017

WVCH Formulary Removals Effective 11/7/2017				
Name	Strength	Dosage Form	Route	Change
Invokana	100 mg, 300 mg	Tablet	Oral	Will allow current members to continue

Questions? Please contact WVCH at 503-584-2150 posted 10.06.2017